TW201733982A - 芳香醯胺類衍生物、其製備方法及其在醫藥上的應用 - Google Patents

芳香醯胺類衍生物、其製備方法及其在醫藥上的應用 Download PDF

Info

Publication number
TW201733982A
TW201733982A TW106109163A TW106109163A TW201733982A TW 201733982 A TW201733982 A TW 201733982A TW 106109163 A TW106109163 A TW 106109163A TW 106109163 A TW106109163 A TW 106109163A TW 201733982 A TW201733982 A TW 201733982A
Authority
TW
Taiwan
Prior art keywords
group
cycloalkyl
heteroaryl
alkyl
compound
Prior art date
Application number
TW106109163A
Other languages
English (en)
Chinese (zh)
Inventor
陸標
苟俊
張民生
賀峰
陶維康
Original Assignee
江蘇恆瑞醫藥股份有限公司
上海恆瑞醫藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江蘇恆瑞醫藥股份有限公司, 上海恆瑞醫藥有限公司 filed Critical 江蘇恆瑞醫藥股份有限公司
Publication of TW201733982A publication Critical patent/TW201733982A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/10Radicals substituted by halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW106109163A 2016-03-18 2017-03-20 芳香醯胺類衍生物、其製備方法及其在醫藥上的應用 TW201733982A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610158675 2016-03-18

Publications (1)

Publication Number Publication Date
TW201733982A true TW201733982A (zh) 2017-10-01

Family

ID=59850085

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106109163A TW201733982A (zh) 2016-03-18 2017-03-20 芳香醯胺類衍生物、其製備方法及其在醫藥上的應用

Country Status (3)

Country Link
CN (1) CN107531679B (fr)
TW (1) TW201733982A (fr)
WO (1) WO2017157332A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201906816A (zh) * 2017-07-06 2019-02-16 大陸商江蘇恆瑞醫藥股份有限公司 吲哚甲醯胺類衍生物、其製備方法及其在醫藥上的應用
EP3683206A4 (fr) * 2017-09-12 2021-01-13 Jiangsu Hengrui Medicine Co., Ltd. Dérivé d'indole-formamide substitué par un atome de deutérium, son procédé de préparation et ses applications médicales
WO2020011147A1 (fr) * 2018-07-10 2020-01-16 Sunshine Lake Pharma Co., Ltd. ANTAGONISTE DE RORγ ET SON UTILISATION EN MÉDECINE
CN110872243B (zh) * 2018-08-31 2023-03-31 四川科伦博泰生物医药股份有限公司 磺酰胺类化合物、其制备方法及用途
WO2020140960A1 (fr) * 2019-01-04 2020-07-09 江苏恒瑞医药股份有限公司 Forme cristalline pour dérivé d'indole-formamide et procédé de préparation de la forme cristalline
TW202100513A (zh) * 2019-03-11 2021-01-01 大陸商江蘇恒瑞醫藥股份有限公司 氘原子取代的吲哚甲酰胺類衍生物的晶型及其製備方法
CN110151760B (zh) * 2019-06-06 2022-02-11 上海海洋大学 双吲哚化合物fgfc1在制备抗非小细胞肺癌药物中的应用
CA3155875A1 (fr) * 2019-09-30 2021-04-08 Shanghai Litedd Co., Ltd. Compose de biaryle substitue par sulfo ou sel correspondant, son procede de preparation et son utilisation
CN112745268B (zh) * 2019-10-31 2022-09-16 江苏恒瑞医药股份有限公司 苯并咪唑衍生物的晶型及制备方法
TW202146381A (zh) * 2020-05-15 2021-12-16 大陸商上海輝启生物醫藥科技有限公司 可用作RORγ調節劑的聯芳基類化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA825413B (en) * 1981-08-26 1983-06-29 Pfizer Thromboxane synthetase inhibitors, processes for their production, and pharmaceutical compositions comprising them
PA8535601A1 (es) * 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
SE0101387D0 (sv) * 2001-04-20 2001-04-20 Astrazeneca Ab Novel compounds
US7820682B2 (en) * 2002-10-03 2010-10-26 Ono Pharmaceutical Co., Ltd. LPA receptor antagonist
KR20090024115A (ko) * 2006-04-12 2009-03-06 에프. 호프만-라 로슈 아게 5-아미도-2-카복스아마이드 인돌
WO2010051245A1 (fr) * 2008-11-03 2010-05-06 Merck Sharp & Dohme Corp. Benzimidazole et aza-benzimidazole carboxamides
HRP20151258T1 (hr) * 2009-08-07 2016-02-26 Chugai Seiyaku Kabushiki Kaisha Derivat aminopirazola
AU2010289353B2 (en) * 2009-09-03 2016-12-08 Allergan, Inc. Compounds as tyrosine kinase modulators
US8883789B2 (en) * 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
WO2014044738A1 (fr) * 2012-09-21 2014-03-27 Sanofi Dérivés d'amide d'acide benzimidazole-carboxylique utilisés comme modulateurs du récepteur apj
WO2015175845A1 (fr) * 2014-05-15 2015-11-19 Peloton Therapeutics, Inc. Dérivés de benzimidazole et leurs utilisations
DK3331876T3 (da) * 2015-08-05 2021-01-11 Vitae Pharmaceuticals Llc Modulators of ror-gamma

Also Published As

Publication number Publication date
CN107531679B (zh) 2021-07-02
WO2017157332A1 (fr) 2017-09-21
CN107531679A (zh) 2018-01-02

Similar Documents

Publication Publication Date Title
CN107531679B (zh) 芳香酰胺类衍生物、其制备方法及其在医药上的应用
CN107428742B (zh) 苯并呋喃类衍生物、其制备方法及其在医药上的应用
KR102425400B1 (ko) Trpm8 길항제로 사용되는 아자스피로 유도체
CN118119600A (zh) Sos1抑制剂及其用途
EP4570794A1 (fr) Composé hétérocyclique pour inhiber et/ou induire la dégradation de la protéine kras
KR101944686B1 (ko) 페닐-3-아자-바이사이클로[3.1.0]헥스-3일-메타논 및 약제로서의 이의 용도
EP4667458A1 (fr) Composition pharmaceutique pour le traitement du cancer, comprenant un inhibiteur de sos1 et un médicament anticancéreux
WO2020238791A1 (fr) Dérivé d'hydropyridopyrimidine, son procédé de préparation et son utilisation médicale
WO2024083258A1 (fr) Agent de dégradation de kras g12c, son procédé de préparation et son utilisation
CN111647000A (zh) 吡嗪类衍生物及其在抑制shp2中的应用
TW202527924A (zh) 多環化合物、製備方法及其醫藥用途
CN105473554A (zh) 作为离子通道调节剂的稠合的哌啶酰胺类
CN113801114A (zh) 稠合二环杂芳基类衍生物、其制备方法及其在医药上的应用
WO2016169421A1 (fr) Dérivé imidazo isoindole, méthode de préparation correspondante et utilisation médicale correspondante
KR20170139144A (ko) 6원 헤테로환 유도체 및 그를 함유하는 의약 조성물
CN109952298B (zh) 吲哚甲酰胺类衍生物、其制备方法及其在医药上的应用
CN108779115B (zh) 五元杂芳环并桥环类衍生物、其制备方法及其在医药上的应用
CN109983015B (zh) 6-吡唑-[1,2,4]三唑并[4,3-a]吡啶-3-酰胺类衍生物、其制备方法及其在医药上的应用
CN109963845B (zh) 螺环甲酰胺类衍生物、其制备方法及其在医药上的应用
CN108779100B (zh) 3,4-二吡啶基吡唑类衍生物、其制备方法及其在医药上的应用
WO2022166810A1 (fr) Dérivé azatricyclique condensé, son procédé de préparation et son utilisation en médecine
WO2017025493A1 (fr) Inhibiteurs quinoléine d'ezh2
TWI848162B (zh) 橋雜環基取代的嘧啶類化合物及其製備方法和醫藥用途
TW201623275A (zh) 噻吩並環烷基或噻吩並雜環基類衍生物、其製備方法及其在醫藥上的應用
WO2025228373A1 (fr) Composé inhibiteur de pan-ras